VYKAT XR shows sustained improvements in hyperphagia and behaviors in Prader-Willi syndrome up to 3 years

VYKAT XR (diazoxide choline) treatment demonstrated significant and lasting improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome (PWS) for up to three years. Participants who resumed VYKAT XR after a 16-week withdrawal showed marked benefits by Week 13, with continued improvements through two years. The Phase 3 program and long-term extension studies confirmed the drug's safety and efficacy compared to real-world data. VYKAT XR is FDA-approved for treating hyperphagia in patients aged 4 and older with PWS, offering a durable treatment option for this rare genetic disorder.